雷米普利对充血性心力衰竭患者Fas/Apo-1水平的影响

目的观察雷米普利对充血性心力衰竭（CHF）患者细胞凋亡抑制因子Fas／Apo-1的影响。方法酶联免疫方法检测84例CHF患者（雷米普利治疗42例；常规治疗42例）治疗前后及30例健康人血清中Fas／Apo-1水平。结果与健康人相比，84例CHF患者Fas／Apo-1水平显著生高（P〈0．01）；CHF患者Fas／Apo-1水平随着心功能损害加重而升高，各组间差异有显著性（P〈0．05）；雷米普利组与常规治疗组治疗前Fas／Apo-1水平两组间差异无显著性（P〉0．05）；与常规治疗组相比，雷米普利组治疗后血清中Fas／Apo-1水平降低更为明显（P〈0．01）。结论CHF患者血清中Fas／Apo-1水平可反映心力衰竭的程度，雷米普利改善CHF患者心脏功能的作用可能与其抑制心肌细胞凋亡的机制有关。

Effect of ramiprili on Fas/Apo-1 in patients with congestive heart failure

Objective] To observe the effect of ramipril on the cardiac function and serum level of Fas/Apo-1 in patients with congestive heart failure (CHF). Methods] Level of serum Fas/Apo-1 was determined by enzyme-linked immunosorbeat assy (ELLSA) in 84 CHF cases (42 treated with ramiprili and 42 with conventional method)and 30 heartly cases as control. Results] The level of serum Fas/Apo-1 in the 84 CHF cases was much higher than that in the control cases (P <0.01)and increased significantly with the aggration of cardiac dysfunction. Before treatment,there was no significant difference in serum level of Fas/Apo-1 between ramiprili group and conventional group, but after treatment, the Fas/Apo-1 level in the ramiprili group was significantly lower (P <0.01)than that in conventional group. Conclusion] Level of circulating Fas/Apo-1 can be used to determine the cardiac dyfunction degree and ramipril may play an important role in protecting cardic function by inhibiting the myocardium apoptosis process in patients with CHF.